Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.